United States drug regulators are removing 160 inactive butalbital products from the exempt prescription product list, effective 30 days after Federal Register publication scheduled for Oct. 9, 2026.
The Drug Enforcement Administration (DEA), the U.S. agency that enforces federal drug laws, has issued a final determination stripping exempt status from 160 butalbital prescription products that are no longer sold, effective 30 days after its publication in the Federal Register1.
The final determination was filed for public inspection on Oct. 8, 2026, as Federal Register document 2026-20757, with publication scheduled for Oct. 9, 20262. It removes the inactive products from the DEA’s Table of Exempted Prescription Products, the official list of drugs spared from certain controlled-substance rules1.
In short, the DEA is cleaning up its list so it shows only butalbital products that are actually on the market. The DEA says the change will have no effect on the listed products, because they are no longer marketed, and products with active drug codes keep their exemption1.
What does the DEA butalbital determination change?
The DEA is revoking the exemption for nonnarcotic prescription products whose National Drug Codes (NDCs) are inactive1. An NDC is the unique identifier the Food and Drug Administration (FDA) assigns to each drug product. The codes are inactive because the products are no longer available, the company that applied for the exemption no longer exists, or both1.
Once removed, these products will no longer count as exempt prescription products under the Controlled Substances Act, the main federal law on drugs with abuse potential1. The determination states plainly that it does not touch exempted products with active NDC numbers1.
The DEA describes the action as a way to accurately portray which products are currently on the market1. The rule sits in 21 CFR Part 1308, the federal regulation that lists controlled-substance schedules, under docket DEA-16641.
Why were butalbital products exempt in the first place?
Butalbital is an intermediate-acting barbiturate, a type of sedative. The DEA classifies it as a schedule III nonnarcotic controlled substance under Controlled Substances Code Number 21001. Schedule III drugs carry federal controls on how they are made, stored and sold.
1967 exemption criteria, per 15 mg of barbiturate
| Second ingredient | Minimum amount |
|---|---|
| Aspirin | 188 mg |
| Salicylamide | 375 mg |
| Phenacetin, acetanilid or acetaminophen | 70 mg |
Some butalbital products were first exempted by the FDA’s Bureau of Drug Abuse Control, a predecessor of the DEA1. A panel of public health physicians and FDA medical officers set the exemption criteria in 19671. The idea was that mixing butalbital with enough of another drug would cause early unpleasant side effects and so discourage abuse1.
For products combining long or intermediate barbiturates with painkillers, the 1967 criteria required a minimum amount of a second ingredient for every 15 mg of barbiturate1:
- at least 188 mg of aspirin;
- at least 375 mg of salicylamide; or
- at least 70 mg of phenacetin, acetanilid, or acetaminophen.
The DEA later approved applications from new manufacturers using the same criteria1. A product that met the 1967 test was treated as meeting the federal legal standard for exemption1.
How many butalbital products lose exempt status?
There are 189 butalbital products listed by NDC on the DEA’s exempt table1. Using the FDA’s National Drug Code Directory and the DailyMed database of the National Library of Medicine, the DEA found that 160 of those codes are no longer active and marketed1. The DEA queried both databases between Jan. 27 and Feb. 3, 20261.
Butalbital products on the DEA exempt table
That leaves 29 listed butalbital products untouched by this action. The DEA also confirmed with the FDA that the 160 products are no longer marketed1.
The removal list names dozens of companies, from large distributors to firms that no longer exist1. It includes products from Alvogen, Cardinal Health, Forest Pharmacal, Mallinckrodt, Mayne Pharma and Nexgen Pharma, among many others1. Mikart, Inc. appears more often than any other company, as maker or manufacturer for many brands1.
The products cover several forms: tablets, capsules, oral solutions and an elixir1. Most contain 50 mg of butalbital per unit, though some contain 25 mg or 30 mg1. Familiar brand names on the list include Esgic, Phrenilin, Bupap, Allzital and Sedapap1.
What did the May 2026 proposal say?
The DEA first proposed the removal in a notice of proposed rulemaking, a draft rule opened for public comment, published on May 26, 20263. That notice, cited as 91 FR 30527, gave the public until June 25, 2026, to comment3.
From proposal to final determination
The proposal invited any company that believed its product was being wrongly removed to say so, if the product was still for sale3. Under DEA rules, an exemption can be revoked only through the same steps used to grant one: a public proposal, a comment period, and a final order setting out the findings3.
How did the DEA answer the single comment?
The DEA received one comment on the proposal1. The commenter worried that the FDA directory and DailyMed may miss some codes. Products made by a contract manufacturer and sold under a private label may carry NDCs that do not appear in either database, the commenter said1.
The commenter asked that all products with currently certified NDC numbers stay on the table1. The DEA replied that entries on its table are specific to each NDC, and a product must carry the exempted NDC on its label1. It said the FDA directory covers certified finished drugs, including repackaged and relabeled ones, so it met the commenter’s request1.
The DEA also contacted the FDA before the proposal and again after the comment to confirm the products were not on the market1. None of the companies directly affected by the removals sent a comment1. The DEA published the final determination without changes1.
Can these butalbital products still be sold?
Yes, under full controls. The DEA notes that a product no longer exempted may still be made and sold, as long as the company and the product meet all DEA rules and the Controlled Substances Act1.
For any firm that revives one of the 160 products, that means treating it as a schedule III controlled substance. Products that remain on the exempt table with active NDCs are not affected1.
Summary of the DEA butalbital exemption removal
The table below sets out the main facts of the final determination.
| Key Dimension | Details |
|---|---|
| Regulating Authority & Jurisdiction | Drug Enforcement Administration, U.S. Department of Justice; 21 CFR Part 13081 |
| Instrument | Final determination, docket DEA-1664, Federal Register document 2026-207572 |
| Scope & Who Must Comply | Makers and distributors of 160 inactive butalbital products on the exempt table1 |
| Core Mandate / Key Change | Products lose exempt status and are removed from the Table of Exempted Prescription Products1 |
| Products Not Affected | Exempted products with active NDC numbers1 |
| Thresholds | 160 of 189 listed butalbital products removed1 |
| Key Dates | Proposal May 26, 2026; comments closed June 25, 20263 |
| Filing and Publication | Filed Oct. 8, 2026; publication scheduled for Oct. 9, 20262 |
| Effective Date | 30 days after Federal Register publication1 |
| Enforcement | Removed products may be sold only in line with all DEA rules and the Controlled Substances Act1 |
The next milestone is the formal publication in the Federal Register, scheduled for Oct. 9, 20262. The removal takes legal effect 30 days after that publication1.
Sources
- ↩ 2026-20757.pdf https://public-inspection.federalregister.gov/2026-20757.pdf
- ↩ Federal Register :: Public Inspection: Schedules of Controlled Substances: Removal of Exemption Status for Inactive Butalbital Products https://www.federalregister.gov/public-inspection/2026-20757/schedules-of-controlled-substances-removal-of-exemption-status-for-inactive-butalbital-products
- ↩ Federal Register :: Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products https://www.federalregister.gov/documents/2026/05/26/2026-10379/schedules-of-controlled-substances-removal-of-exemption-status-for-inactive-butalbital-products